CDMO Market Opportunities and Competitive Landscape

The CDMO Market was valued at USD 136.6 billion in 2024, and is projected to reach USD 191.6 billion by 2029, rising at a CAGR of 7%.

The CDMO sector is dynamic and offers service providers a wealth of opportunities for expansion. As the CDMO sector is trending toward consolidation, CDMO businesses are shifting focus to become one-stop shops or integrated pharmaceutical service providers.

Report Scope

This report provides an overview of the pharmaceutical business and the function of contract development and manufacturing organizations (CDMOs). The analysis includes a review of the global CDMO market by service type, drug molecule type and end use. It also examines the regulatory policies, standards and inspection trends of the global CDMO markets. In addition, the competitive environment, significant rivals, significant leaders and top 10 manufacturers in the CDMO sector are also reviewed.

The report presents a detailed description of the service types (API manufacturing services, drug product/finished drug manufacturing service, pharmaceutical development services and analytical testing and regulatory support services) and current and historical market revenues. The CDMO markets are also segmented based on type of molecule (small-molecule drugs, biologics and advanced therapies) and end user (clinical and commercial). The market revenue for each geographic segment (North America, Europe, Asia-Pacific and the Rest of the World) has also been provided in the report.

In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also included in this report. For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

The report includes:

76 data tables and 32 additional tables
An overview of the global contract development and manufacturing organization (CDMO) market
Analysis of the global market trends, with data from 2021-2022, estimates for 2023, forecast for 2024, and projections of compound annual growth rates (CAGRs) through 2029
Estimates of the market size and revenue forecast for the CDMO market, and a corresponding market share analysis based on type of service, drug molecule type, end user, and region
Evaluation of the market potential and opportunities for pharmaceutical CDMOs, regulatory policies, standards and inspection trends
Identifying the pharma companies that are considered leaders in their field, as well as the technological means these companies are using to exploit their markets
A look at the competitive landscape of the global CDMO market, featuring companies contracting with a contract manufacturing outsourcer for both clinical and commercial stage manufacturing
A discussion of the ESG challenges and practices in the CDMO industry
An analysis of the market shares of key companies in the industry as well as their proprietary technologies and strategic alliances
Profiles of the leading players, including Thermo Fisher Scientific Inc., Merck KGaA, Lonza, Catalent Inc., and WuXi AppTec

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
Value Chain Analysis
Small-Molecule Drugs
Biologics
Advanced Therapy Medical Products
PESTEL Analysis of the Pharmaceutical Industry
Political Factors
Economic Factors
Social Factors
Technological Factors
Environmental Factors
Legal Factors

Chapter 3 Market Dynamics

Global Market Dynamics
Market Drivers
Increase in Pharmaceutical Outsourcing Practices
Pressure on R&D Spending
Rising Demand for Advanced Therapeutics
Upsurge in the Number of Clinical Trials
Market Restraints
Strict Regulations and Compliance Requirements
Shortage of Skilled Technical Personnel
Strong Competition in Cost, Technology and Service Ranges
Market Opportunities
Inorganic Growth

Chapter 4 Emerging Trends

Overview
Increased Focus on Biologics and Cell and Gene Therapy
Integration of Digital Technologies
Collaborative Risk Management

Chapter 5 Regulatory Landscape

Overview
Good Manufacturing Practice (GMP)
Quality Assurance and Quality Control
Regulatory Submissions
Environmental & Safety Regulations
International Standards
Data Integrity & Security
Labeling & Packaging
Audits and Inspections

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Market Breakdown by Type of Service
API Manufacturing Services
Drug Product/Finished Drug Manufacturing Services
Pharmaceutical Development Services
Analytical Testing and Regulatory Support Services
Market Breakdown by Type of Molecule
Small-molecule Drugs
Biologics
Advanced Therapies
Market Breakdown by End User
Clinical
Commercial
Geographic Breakdown
Market Breakdown by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence

Overview
New Entrants in Market
Global Market Shares of Leading Companies

Chapter 8 Sustainability in CDMO Market: ESG Perspective

Overview
Green Chemistry and Pharmaceutical Manufacturing
Considering Sustainability through the Development Cycle and Across the Supply Chain
Sustainability in the CDMO industry
Environmental Considerations
Social Considerations
Governance Factors
ESG Risk Ratings
Conclusion

Chapter 9 Appendix

Methodology
Sources
Abbreviations
Company Profiles
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
CATALENT INC.
FUJIFILM DIOSYNTH BIOTECHNOLOGIES
LONZA
MERCK KGAA
RECIPHARM AB
SAMSUNG BIOLOGICS
SIEGFRIED HOLDING AG
THERMO FISHER SCIENTIFIC INC.
WUXI APPTEC

List of Tables

Summary Table: Global CDMO Market, by Type of Service, Through 2029
Table 1: Global CDMO Market, by Type of Service, Through 2029
Table 2: Global CDMO Market for API Manufacturing Services, by Region, Through 2029
Table 3: Global CDMO Market for Drug Product/Finished Drug Manufacturing Services, by Region, Through 2029
Table 4: Global CDMO Market for Pharmaceutical Development Services, by Region, Through 2029
Table 5: Global CDMO Market for Analytical Testing and Regulatory Support Services, by Region, Through 2029
Table 6: Global CDMO Market, by Type of Molecule, Through 2029
Table 7: Global CDMO Market for Small-molecule Drugs, by Region, Through 2029
Table 8: Global CDMO Market for Biologics, by Region, Through 2029
Table 9: Global CDMO Market for Advanced Therapies, by Region, Through 2029
Table 10: Global CDMO Market, by End User, Through 2029
Table 11: Global CDMO Market for Clinical Services, by Region, Through 2029
Table 12: Global CDMO Market for Commercial Services, by Region, Through 2029
Table 13: Global Market for CDMO, by Region, Through 2029
Table 14: North American CDMO Market, by Types of Service, Through 2029
Table 15: North American CDMO Market, by Type of Molecule, Through 2029
Table 16: North American CDMO Market, by End User, Through 2029
Table 17: North American Market for CDMO, by Country, Through 2029
Table 18: The U.S. CDMO Market, by Types of Service, Through 2029
Table 19: The U.S. CDMO Market, by Type of Molecule, Through 2029
Table 20: The U.S. CDMO Market, by End User, Through 2029
Table 21: Canadian CDMO Market, by Types of Service, Through 2029
Table 22: Canadian CDMO Market, by Type of Molecule, Through 2029
Table 23: Canadian CDMO Market, by End User, Through 2029
Table 24: Mexican CDMO Market, by Types of Service, Through 2029
Table 25: Mexican CDMO Market, by Type of Molecule, Through 2029
Table 26: Mexican CDMO Market, by End User, Through 2029
Table 27: European CDMO Market, by Types of Service, Through 2029
Table 28: European CDMO Market, by Type of Molecule, Through 2029
Table 29: European CDMO Market, by End User, Through 2029
Table 30: European Market for CDMO Market, by Country, Through 2029
Table 31: German CDMO Market, by Types of Service, Through 2029
Table 32: German CDMO Market, by Type of Molecule, Through 2029
Table 33: German CDMO Market, by End User, Through 2029
Table 34: The U.K. CDMO Market, by Types of Service, Through 2029
Table 35: The U.K. CDMO Market, by Type of Molecule, Through 2029
Table 36: The U.K. CDMO Market, by End User, Through 2029
Table 37: French CDMO Market, by Types of Service, Through 2029
Table 38: French CDMO Market, by Type of Molecule, Through 2029
Table 39: French CDMO Market, by End User, Through 2029
Table 40: Spanish CDMO Market, by Types of Service, Through 2029
Table 41: Spanish CDMO Market, by Type of Molecule, Through 2029
Table 42: Spanish CDMO Market, by End User, Through 2029
Table 43: Italian CDMO Market, by Types of Service, Through 2029
Table 44: Italian CDMO Market, by Type of Molecule, Through 2029
Table 45: Italian CDMO Market, by End User, Through 2029
Table 46: Rest of European Countries’ CDMO Market, by Types of Service, Through 2029
Table 47: Rest of European Countries’ CDMO Market, by Type of Molecule, Through 2029
Table 48: Rest of European Countries’ CDMO Market, by End User, Through 2029
Table 49: Asia-Pacific CDMO Market, by Types of Service, Through 2029
Table 50: Asia-Pacific CDMO Market, by Type of Molecule, Through 2029
Table 51: Asia-Pacific CDMO Market, by End User, Through 2029
Table 52: Asia-Pacific Market for CDMO, by Country, Through 2029
Table 53: Chinese CDMO Market, by Types of Service, Through 2029
Table 54: Chinese CDMO Market, by Type of Molecule, Through 2029
Table 55: Chinese CDMO Market, by End User, Through 2029
Table 56: Japanese CDMO Market, by Types of Service, Through 2029
Table 57: Japanese CDMO Market, by Type of Molecule, Through 2029
Table 58: Japanese CDMO Market, by End User, Through 2029
Table 59: Indian CDMO Market, by Types of Service, Through 2029
Table 60: Indian CDMO Market, by Type of Molecule, Through 2029
Table 61: Indian CDMO Market, by End User, Through 2029
Table 62: Rest of Asia-Pacific CDMO Market, by Types of Service, Through 2029
Table 63: Rest of Asia-Pacific CDMO Market, by Type of Molecule, Through 2029
Table 64: Rest of Asia-Pacific CDMO Market, by End User, Through 2029
Table 65: Rest of the World CDMO Market, by Types of Service, Through 2029
Table 66: Rest of the World CDMO Market, by Type of Molecule, Through 2029
Table 67: Rest of the World CDMO Market, by End User, Through 2029
Table 68: ESG Risk Rankings for CDMO Companies, 2024*
Table 69: Information Sources in this Report
Table 70: Glossary of Terms Used in the Global CDMO Market
Table 71: Boehringer Ingelheim International GmbH: Company Snapshot
Table 72: Boehringer Ingelheim International GmbH: Financial Performance, FY 2022 and 2023
Table 73: Boehringer Ingelheim International GmbH: Product Portfolio
Table 74: Boehringer Ingelheim International GmbH: News/Recent Developments, 2021
Table 75: Catalent Inc.: Company Snapshot
Table 76: Catalent Inc.: Financial Performance, FY 2022 and 2023
Table 77: Catalent Inc.: Product Portfolio
Table 78: Catalent Inc.: News/Key Developments, 2022-2024
Table 79: Fujifilm Diosynth Biotechnologies: Company Snapshot
Table 80: Fujifilm Diosynth Biotechnologies: Product Portfolio
Table 81: Fujifilm Diosynth Biotechnologies: News/Key Developments, 2021-2024
Table 82: Lonza: Company Snapshot
Table 83: Lonza: Financial Performance, FY 2022 and 2023
Table 84: Lonza: Product Portfolio
Table 85: Lonza: News/Key Developments, 2022-2024
Table 86: Merck KGaA: Company Snapshot
Table 87: Merck KGaA: Financial Performance, FY 2022 and 2023
Table 88: Merck KGaA: Product Portfolio
Table 89: Merck KGaA: News/Key Developments, 2022
Table 90: Recipharm AB: Company Snapshot
Table 91: Recipharm AB: Product Portfolio
Table 92: Recipharm AB: News/Key Developments, 2021-2024
Table 93: Samsung Biologics: Company Snapshot
Table 94: Samsung Biologics: Financial Performance, FY 2022 and 2023
Table 95: Samsung Biologics: Product Portfolio
Table 96: Samsung Biologics: News/Key Developments, 2021-2024
Table 97: Siegfried Holding AG: Company Snapshot
Table 98: Siegfried Holding AG: Financial Performance, FY 2022 and 2023
Table 99: Siegfried Holding AG: Product Portfolio
Table 100: Siegfried Holding AG: News/Key Developments, 2022-2024
Table 101: Thermo Fisher Scientific Inc.: Company Snapshot
Table 102: Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 103: Thermo Fisher Scientific Inc.: Product Portfolio
Table 104: WuXi AppTec: Company Snapshot
Table 105: WuXi AppTec: Financial Performance, FY 2022 and 2023
Table 106: WuXi AppTec: Product Portfolio
Table 107: WuXi AppTec: News/Key Developments, 2022-2024

List of Figures

Summary Figure: Global CDMO Market, by Type of Service, 2021-2029
Figure 1: Pharma Services Value Chain
Figure 2: Market Dynamics of Global CDMO Market
Figure 3: Global CDMO Market Share, by Type of Service, 2023
Figure 4: Global CDMO Market Share for API Manufacturing Services, by Region, 2023
Figure 5: Global CDMO Market Share for Drug Product/Finished Drug Manufacturing Services, by Region, 2023
Figure 6: Global CDMO Market Share for Pharmaceutical Development Services, by Region, 2023
Figure 7: Global CDMO Market Share for Analytical Testing and Regulatory Support Services, by Region, 2023
Figure 8: Global CDMO Market Share, by Type of Molecule, 2023
Figure 9: Small-molecule NCE and Biologics Approved by FDA, 2018-2023
Figure 10: Global CDMO Market Share for Small-molecule Drugs, by Region, 2023
Figure 11: Global CDMO Market Share for Biologics, by Region, 2023
Figure 12: Global CDMO Market Share for Advanced Therapies, by Region, 2023
Figure 13: Global CDMO Market Share, by End User, 2023
Figure 14: Global CDMO Market Share for Clinical Services, by Region, 2023
Figure 15: Global CDMO Market Share for Commercial Services, by Region, 2023
Figure 16: Global CDMO Market Share, by Region, 2023
Figure 17: North American CDMO Market Share, by Types of Service, 2023
Figure 18: North American CDMO Market Share, by Type of Molecule, 2023
Figure 19: North American CDMO Market Share, by End User, 2023
Figure 20: North American CDMO Market Share, by Country, 2023
Figure 21: European CDMO Market Share, by Types of Service, 2023
Figure 22: European CDMO Market Share, by Type of Molecule, 2023
Figure 23: European CDMO Market Share, by End User, 2023
Figure 24: European CDMO Market Share, by Country, 2023
Figure 25: Asia-Pacific CDMO Market Share, by Types of Service, 2023
Figure 26: Asia-Pacific CDMO Market Share, by Type of Molecule, 2023
Figure 27: Asia-Pacific CDMO Market Share, by End User, 2023
Figure 28: Asia-Pacific CDMO Market Share, by Country, 2023
Figure 29: Rest of the World CDMO Market Share, by Types of Service, 2023
Figure 30: Rest of the World CDMO Market Share, by Type of Molecule, 2023
Figure 31: Rest of the World CDMO Market Share, by End User, 2023
Figure 32: Global Company Share Analysis of CDMO, 2023
Figure 33: Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit, FY 2023
Figure 34: Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country, FY 2023
Figure 35: Catalent Inc.: Revenue Share, by Business Unit, FY 2023
Figure 36: Catalent Inc.: Revenue Share, by Country/Region, FY 2023
Figure 37: Lonza: Revenue Share, by Business Unit, FY 2023
Figure 38: Lonza: Revenue Share, by Country/Region, FY 2023
Figure 39: Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 40: Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 41: Samsung Biologics: Revenue Share, by Business Unit, FY 2023
Figure 42: Samsung Biologics: Revenue Share, by Country/Region, FY 2023
Figure 43: Siegfried Holding AG: Revenue Share, by Business Unit, FY 2023
Figure 44: Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 45: Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023
Figure 46: WuXi AppTec: Revenue Share, by Business Unit, FY 2023
Figure 47: WuXi AppTec: Revenue Share, by Country/Region, FY 2023

Companies Mentioned

Boehringer Ingelheim International GmbH
Catalent Inc.
Fujifilm Diosynth Biotechnologies
Lonza
Merck KGaA
Recipharm AB
Samsung Biologics
Siegfried Holding AG
Thermo Fisher Scientific Inc.
Wuxi Apptec

Table Information

Report Attribute	Details
No. of Pages	130
Published	November 2024
Forecast Period	2024 - 2029
Estimated Market Value ( USD ) in 2024	$ 136.6 Billion
Forecasted Market Value ( USD ) by 2029	$ 191.6 Billion
Compound Annual Growth Rate	7.0%
Regions Covered	Global
No. of Companies Mentioned	10

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4579EUR$4,650USD£3,794GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€5494EUR$5,580USD£4,553GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6593EUR$6,696USD£5,464GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€7912EUR$8,035USD£6,556GBP

Report Scope

The report includes:

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Contract Development and Manufacturing Organization (CDMO) Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, and Product Type

Large Molecule Drug Substance CDMO Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F

Biologics CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Small Molecule CMO/CDMO Global Market Report 2024

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)